A new live respiratory syncytial virus (RSV) vaccine holds promise against the infection, suggests a recent trial.
- RSV seronegative children between 6 and 24 months of age were given either intranasal doses of a placebo of RSV cold-passage/stabilized 2 (RSVcps2) vaccine, a previously studied product that was altered with mutations to stabilize it against diattenuation.
- 85% of the children were RSVcps2, 77% shed vaccine virus, and 59% developed at least a 4-fold increase in neutralizing antibody titers.
- Placebo and vaccine recipients both experienced a 50% rate of respiratory tract, febrile illness, or both.
Buchholz UJ, Cunningham CK, Muresan P, et al. Live respiratory syncytial virus (RSV) vaccine candidate containing stabilized temperature-sensitivity mutations is highly attenuated in RSV-seronegative infants and children. [Published online ahead of print March 2, 2018]. J Infect Dis. doi:10.1093/infdis/jiy066.
This Week's Must Reads
USPSTF: Screening for Prostate Cancer, JAMA; 2018 May 8; Grossman, et al
Smoke-Free Policies and Risk of CVD , Circulation; ePub 2018 May 7; Mayne, et al
Psychological Interventions & Chronic Pain Reduction, JAMA Intern Med; ePub 2018 May 7; Niknejad, et al
Managing Blood Pressure in a Primary Care Setting, J Am Board Fam Med; 2018 May-Jun; Doane, et al
Cancer Incidence Rates in HIV-Infected Adults, Ann Intern Med; ePub 2018 May 8; Shiels, et al
Must Reads in Vaccines
Does an Adult Tdap Booster Makes Sense?, J Pediatr Infect Dis Soc; 2018 Feb 8; Halperin, et al
Vaccine Exposure & Non-Vaccine Related Infection, JAMA Pediatr; 2018 Mar 6; Glanz, et al
Developing Cost Effective Typhoid Fever Vaccines , J Infect Dis; ePub 2018 Feb 12; Lo, Gupta, et al
Ineffective Pneumococcal Vaccine in Children, Open Forum Infect Dis; ePub 2018 Feb 17; Martin, et al
Genetically Redesigned RSV Vaccine is Promising , J Infect Dis; ePub 2018 Mar 2; Buchholz, et al